| Market Capitalization (Millions $) |
17 |
| Shares
Outstanding (Millions) |
27 |
| Employees |
582 |
| Revenues (TTM) (Millions $) |
174 |
| Net Income (TTM) (Millions $) |
-235 |
| Cash Flow (TTM) (Millions $) |
-135 |
| Capital Exp. (TTM) (Millions $) |
7 |
Business Description
The company known as 23andMe Holding Co., previously named VG Acquisition Corp., is dedicated to assisting individuals in living healthier lives. Their goal is to help people access, comprehend and benefit from the human genome. They believe that their extensive database of genetic and phenotypic information can revolutionize healthcare. They obtain this data from millions of customers who separately consent to participate in their research. The company is committed to ethical, scientific, and privacy standards to provide trustworthy health and genetic information.
23andMe Holding Co. was the first to provide direct-to-consumer genetic testing, allowing individuals to have access to unique, personalized genetic health risks, ancestry, and traits. The company has multiple Food and Drug Administration ("FDA") authorizations for over-the-counter health and carrier status reports. 23andMe Holding Co. is the only company to obtain FDA authorization for all carrier status, genetic health risk, cancer predisposition, and pharmacogenetics reports. Customers can choose from over 60 health reports in the U.S.
In November 2021, 23andMe Holding Co. acquired Lemonaid Health, Inc., making personalized healthcare accessible for all. Lemonaid offers affordable and direct online access to medical care, from consultation through treatment, for a variety of common conditions, using evidence-based guidelines and clinical protocols to provide quality patient care. Patients can use the online pharmacy for fast and free delivery when prescribed medication by medical professionals.
The company operates in two reporting segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment includes the Personal Genome Servicee (ePGSe), telehealth services, and research services. The PGS service provides customers with genetic reports on ancestral origins, personal genetic health risks, and the chances of passing on rare carrier conditions to their children. Customers can access PGS services on the website, 23andMe.com, or mobile app. Customers can upgrade from the Ancestry + Traits Service to the Health + Ancestry Service for a fee. 23andMe+ premium subscription service offers customers the Health + Ancestry Service, pharmacogenetic reports, personalized genetic risk reports, and advanced ancestry and health features. The company's research programs allow customers to participate voluntarily. 80% of customers have participated in the programs. The company analyzes the data provided by the customers and uses proprietary machine learning techniques to gain insight into how genetic variants affect the likelihood of individuals developing specific diseases.
The telehealth segment provides patients with medical consultation and treatment from one of their affiliated licensed physicians or nurse practitioners via telehealth. Patients can access the online pharmacy for fast and free delivery of non-controlled medications for acute and chronic conditions at affordable prices. The Consumer & Research Services segment accounts for the majority of the company's revenue.
Company Address: 870 Market Street, Room 415 San Francisco, 94102 CA
Company Phone Number: 938-6300 Stock Exchange / Ticker: ME
|
0.000%
0.92% 
78.04 %